TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

Launched by CHILDREN'S HOSPITAL MEDICAL CENTER, CINCINNATI · Sep 20, 2019

Keywords

ClinConnect Summary

The TRANSPIRE trial is studying how lung injuries affect children who have undergone a hematopoietic stem cell transplant (HSCT). This treatment can help with various blood disorders, but it can also lead to serious lung problems in some young patients. The study aims to understand how often these lung injuries happen, what causes them, and how to diagnose and treat them more effectively. By gathering information from a large group of children receiving HSCT, researchers hope to find better ways to recognize and manage these complications early on.

To be eligible for this study, participants must be 24 years old or younger and undergoing either an allogeneic (from a donor) or autologous (from themselves) HSCT. Those who join the trial can expect to be part of a team that will monitor their lung health over time and may contribute to developing improved tests and treatments for lung issues after transplant. This research is especially important as more children are receiving HSCT for conditions like sickle cell disease, and understanding lung complications can help improve their overall health and recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects ≤ 24 years of age undergoing allogeneic or autologous HSCT.
• Exclusion Criteria:
• • Subjects over 24 years of age.